Systemic Infiltration of FDA by Special Interests Undermines Rare Disease Treatments
Original framing: “Political influence ‘a serious problem’ for FDA under Trump, former commissioner says” — STAT News
The FDA's regulatory capture is not a new phenomenon, dating back to the 1970s when the agency began to rely heavily on industry funding. This historical context is essential to understanding the current state of affairs and the need for systemic reforms.
The FDA's handling of rare disease treatments is a symptom of a broader problem within the agency's regulatory framework.
The infiltration of special interests has compromised the agency's ability to handle the complexities of new therapeutics, hindering the availability of hundreds of individualized treatments. A comprehensive review of the FDA's regulatory framework is needed, incorporating measures to increase transparency, reduce industry influence, and enhance the agency's capacity for scientific decision-making. This should be accompanied by a more holistic approach to healthcare policy, incorporating traditional knowledge and practices to address the root causes of disease. Ultimately, the needs of marginalized communities, including those with rare diseases, must be addressed through a more inclusive approach to healthcare policy.